title: Transfusion Therapy in Children With Sickle Cell Disease.
abstract: Hydroxyurea, blood transfusions, and hematopoietic stem cell transplantation represent the 3 disease-modifying therapies in children with sickle cell disease (SCD). Blood transfusions play an increasingly important role in both prevention and management of SCD complications in this age group. This review will focus on the indications of blood transfusion in children with SCD and modalities of its administration. It will also highlight the complications of this life-saving therapy and ways of optimizing transfusion to minimize its associated risks.
authors: *Department of Pediatrics, Lebanese American University and University Medical Center Rizk Hospital, Beirut †School of Medicine, Lebanese American University, Byblos, Lebanon ‡Department of Molecular and Cellular Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX.
authors: Adlette
authors: A
authors: Inati
authors: Anthony G
authors: AG
authors: Mansour
authors: Toni
authors: T
authors: Sabbouh
authors: Ghid
authors: G
authors: Amhez
authors: Ahmad
authors: A
authors: Hachem
authors: Hussein A
authors: HA
authors: Abbas
mesh_terms: D000755:Anemia, Sickle Cell / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D001787:Blood Group Incompatibility / Q000209:etiology / Q000276:immunology; D001803:Blood Transfusion / Q000379:methods; D001809:Blood Viscosity; D017848:Blood-Borne Pathogens; D003131:Combined Modality Therapy; D005078:Exchange Transfusion, Whole Blood; D005544:Forecasting; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D009102:Multiple Organ Failure / Q000517:prevention & control; D013156:Splenectomy; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D065227:Transfusion Reaction
chemical_list: D007502:Iron Chelating Agents